Pure Bioscience, INC.: management transactions · United States · SEC (Form 4)

About Pure Bioscience, INC.

PURE Bioscience, Inc. is a U.S.-based specialty small-cap company that is followed by investors for SEC insider activity and other regulatory filings, rather than as a mainstream large-cap healthcare name. The company is registered in the United States and is headquartered in El Cajon, California, in the San Diego area. Its roots go back to 1992, when it was incorporated as Innovative Medical Services; it later adopted the PURE Bioscience name as it shifted away from legacy water-treatment activities and toward bioscience and antimicrobial technologies. In today’s form, PURE is best understood as a focused developer and commercializer of stabilized-silver antimicrobial solutions, especially its proprietary silver dihydrogen citrate (SDC) platform, which the company markets as a non-toxic approach to pathogen control and hygiene. Operationally, PURE is not a broad diversified life-sciences group. It is centered on one primary business line: the development, commercialization, and sale of antimicrobial products for professional use. SEC disclosures indicate that the company sells through end-user and distribution channels and is working to turn product evaluations and trials into repeat orders. That gives PURE a clearly defined niche in cleaning, sanitation, and microbial-control applications, particularly where customers value efficacy, safety, and regulatory positioning. At the same time, its competitive profile is that of a very small player facing much larger and better-capitalized chemical, disinfectant, and hygiene-product companies. Recent SEC filings suggest a business that remains small but is showing some progress. For the fiscal year ended July 31, 2025, PURE reported net product sales of $2.198 million, up from the prior year, and a net loss of about $2.4 million, improved from roughly $3.4 million in fiscal 2024, helped by significant reductions in personnel, facility, and board-related expenses. In May 2026, the company also filed a Form 8-K describing a material definitive agreement and unregistered sales of equity securities, underscoring that financing and capital structure remain important considerations. For international investors, PURE should be viewed as a speculative microcap within the health/antimicrobial space: the investment case depends on commercial adoption of the SDC platform, continued cost discipline, and the company’s ability to fund execution in the United States market.